PropertyValue
?:abstract
  • Purpose: Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (RNT) may increase tumor immunogenicity. We aimed at exploiting this effect by combining RNT with immunotherapy in a mouse model of prostate cancer (PC). Experimental Design: C57BL/6-mice bearing syngeneic RM1-PGLS tumors were treated with 225Ac-PSMA617, an anti-PD-1 antibody, or both. Therapeutic efficacy was assessed by tumor volume measurements (computed tomography), time to progression (TTP) and survival. Results: PSMA-RNT or anti-PD-1 alone tended to prolong TTP (isotype-control 25d; anti-PD-1 33.5d, p=0.0153; RNT 30d, p=0.1038) and survival (control 28d; anti-PD-1 37d, p=0.0098; RNT 32d, p=0.1018). Combining PSMA-RNT and anti-PD-1 significantly improved disease control compared to either monotherapy. TTP was extended to 47.5d (p<0.0199 vs. monotherapies), and survival to 51.5d (p<0.0251 vs. monotherapies). Conclusion : PSMA-RNT and PD-1 blockade synergistically improve therapeutic outcomes in our PC model, supporting the evaluation of RNT/immunotherapy combinations for PC patients.
is ?:annotates of
?:creator
?:journal
  • J._nucl._med
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
?:type
?:who_covidence_id
  • #32646877
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/m3241zyk>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/m3241zyk>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all